Taiwan · Delayed Price · Currency is TWD OK Biotech Statistics
Total Valuation
OK Biotech has a market cap or net worth of TWD 2.09 billion. The enterprise value is 2.83 billion.
| Market Cap | 2.09B |
| Enterprise Value | 2.83B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
OK Biotech has 141.12 million shares outstanding. The number of shares has decreased by -0.43% in one year.
| Current Share Class | 141.12M |
| Shares Outstanding | 141.12M |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -7.95% |
| Owned by Insiders (%) | 4.63% |
| Owned by Institutions (%) | 0.32% |
| Float | 101.81M |
Valuation Ratios
The trailing PE ratio is 18.87.
| PE Ratio | 18.87 |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | 107.08 |
| P/OCF Ratio | 6.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.78, with an EV/FCF ratio of 145.14.
| EV / Earnings | 25.05 |
| EV / Sales | 1.85 |
| EV / EBITDA | 11.78 |
| EV / EBIT | 18.98 |
| EV / FCF | 145.14 |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.38.
| Current Ratio | 2.49 |
| Quick Ratio | 1.50 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | 4.19 |
| Debt / FCF | 51.08 |
| Interest Coverage | 14.00 |
Financial Efficiency
Return on equity (ROE) is 5.16% and return on invested capital (ROIC) is 4.23%.
| Return on Equity (ROE) | 5.16% |
| Return on Assets (ROA) | 2.38% |
| Return on Invested Capital (ROIC) | 4.23% |
| Return on Capital Employed (ROCE) | 4.34% |
| Weighted Average Cost of Capital (WACC) | 3.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, OK Biotech has paid 8.23 million in taxes.
| Income Tax | 8.23M |
| Effective Tax Rate | 5.84% |
Stock Price Statistics
The stock price has decreased by -14.70% in the last 52 weeks. The beta is 0.18, so OK Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -14.70% |
| 50-Day Moving Average | 13.59 |
| 200-Day Moving Average | 14.56 |
| Relative Strength Index (RSI) | 63.59 |
| Average Volume (20 Days) | 593,064 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OK Biotech had revenue of TWD 1.53 billion and earned 113.01 million in profits. Earnings per share was 0.78.
| Revenue | 1.53B |
| Gross Profit | 448.04M |
| Operating Income | 146.52M |
| Pretax Income | 140.86M |
| Net Income | 113.01M |
| EBITDA | 224.48M |
| EBIT | 146.52M |
| Earnings Per Share (EPS) | 0.78 |
Balance Sheet
The company has 317.98 million in cash and 996.26 million in debt, with a net cash position of -678.28 million or -4.81 per share.
| Cash & Cash Equivalents | 317.98M |
| Total Debt | 996.26M |
| Net Cash | -678.28M |
| Net Cash Per Share | -4.81 |
| Equity (Book Value) | 2.59B |
| Book Value Per Share | 17.80 |
| Working Capital | 760.39M |
Cash Flow
In the last 12 months, operating cash flow was 342.30 million and capital expenditures -322.79 million, giving a free cash flow of 19.51 million.
| Operating Cash Flow | 342.30M |
| Capital Expenditures | -322.79M |
| Depreciation & Amortization | 77.96M |
| Net Borrowing | 71.69M |
| Free Cash Flow | 19.51M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 29.33%, with operating and profit margins of 9.59% and 7.40%.
| Gross Margin | 29.33% |
| Operating Margin | 9.59% |
| Pretax Margin | 9.22% |
| Profit Margin | 7.40% |
| EBITDA Margin | 14.69% |
| EBIT Margin | 9.59% |
| FCF Margin | 1.28% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 2.03%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 2.03% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 38.75% |
| Buyback Yield | 0.43% |
| Shareholder Yield | 2.45% |
| Earnings Yield | 5.41% |
| FCF Yield | 0.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2023. It was a forward split with a ratio of 1.10213412.
| Last Split Date | Sep 6, 2023 |
| Split Type | Forward |
| Split Ratio | 1.10213412 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |